Financial Results Overview

Standalone Financials (FY2025-26):

  • Total Income: ₹7,431.39 crores (up from previous year)
  • Revenue from Operations: ₹7,336.75 crores
  • Other Income: ₹94.64 crores
  • EBITDA before forex, other income and exceptional items: ₹1,847.36 crores
  • Finance Costs: ₹43.51 crores
  • Depreciation and Amortization: ₹268.87 crores
  • Tax Expense: ₹399.61 crores
  • Net Profit before exceptional items: ₹1,162.94 crores (up 25% YoY)
  • Exceptional Items: ₹30.42 crores (Impact of new Labour Codes)
  • Net Profit after exceptional items: ₹1,132.52 crores (up 74% YoY)
  • Earnings Per Share (before exceptional): ₹45.84
  • Earnings Per Share (after exceptional): ₹44.64

Consolidated Financials (FY2025-26):

  • Revenue from Operations: ₹9,646.33 crores
  • Other Income: ₹174.45 crores
  • Total Income: ₹9,820.78 crores
  • Net Profit attributable to owners: ₹1,141.12 crores (up 55% YoY)
  • EPS (before exceptional): ₹46.94
  • EPS (after exceptional): ₹44.98

Quarterly Performance (Q4 FY26)

Standalone:

  • Revenue from Operations: ₹1,814.35 crores (up 11% YoY)
  • Net Profit before exceptional items: ₹292.71 crores (up 35% YoY)
  • Net Profit after exceptional items: ₹262.29 crores

Consolidated:

  • Revenue from Operations: ₹2,388.48 crores
  • Net Profit attributable to owners: ₹299.07 crores (up 341% YoY)

Dividend Recommendation

The Board has recommended a dividend of ₹6 per equity share of face value ₹1 each (600%) for the financial year ended March 31, 2026. This is subject to approval of shareholders at the ensuing Annual General Meeting. The company has fixed Friday, August 7, 2026 as the Record Date for determining members' entitlement to the dividend.

Management Reappointment

The Board approved the re-appointment of Mr. Prashant Godha (DIN: 00012759) as Executive Director for a further period of 5 years effective from August 16, 2026, subject to shareholder approval.

Profile Details:

  • Age: 51 years
  • Education: Graduate in Commerce, Post Graduate Diploma in Business Management
  • Experience: Over 20 years in pharmaceuticals marketing and general management
  • Previous Roles: Appointed Additional Director from July 28, 2011 and Executive Director from August 16, 2011
  • Relationships: Related to Mr. Premchand Godha (Executive Chairman) and Mr. Pranay Godha (Managing Director & CEO)
  • Not debarred from holding director office by any authority

Exceptional Items Disclosure

Standalone Exceptional Items (₹30.42 crores):

  • Impact of new Labour Codes: ₹30.42 crores (₹10.31 crores initial assessment + ₹20.11 crores from revised pay structure)

Prior Year Standalone Exceptional Items (₹281.54 crores):

  • Impairment of exposure in subsidiary (Ipca Pharmaceuticals Inc., USA): ₹173.00 crores
  • Impairment of exposure in associate (Krebs Biochemicals & Industries Ltd.): ₹108.54 crores

Consolidated Exceptional Items (₹86.43 crores):

  • Interest settlement of European Commission: ₹58.26 crores
  • Impact of new Labour Codes: ₹45.82 crores
  • Net gain on disposal of land & building: (₹17.65) crores

Prior Year Consolidated Exceptional Items (₹205.05 crores):

  • Impairment of exposure in associate: ₹118.90 crores
  • Impairment of fair value of Freehold Land of subsidiary: ₹86.15 crores

Segment Information

The company has only one operating segment - 'Pharmaceuticals'. Geographic revenue breakdown:

  • India: ₹4,386.62 crores (45% of total)
  • Outside India: ₹5,259.71 crores (55% of total)

Board Meeting Details

The Board meeting started at 11:30 AM and concluded at 1:45 PM on May 29, 2026.